DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals Inc.

Endo Health Solutions said today it is acquiring Canadian-based specialty pharma company Paladin Labs for roughly $1.6 billion, in a stock and cash deal that expands the buyer’s global presence, ...

DUBLIN, Jan. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with Radius Health, Inc.

MALVERN, Pa., Feb. 26, 2014 /PRNewswire/ -- Endo Health Solutions Inc. (NASDAQ: ENDP) ("Endo") today announced that, at the shareholder meeting held today, proposals related to Endo's proposed ...

DUBLIN and LUGANO, Switzerland, July 31, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are ...

Endo Health Solutions Inc. ENDP agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. (PLDLF, PLB.T) for about $1.6 billion, allowing Endo to continue its transition into a ...

(Reuters) - Endo International Plc has discussed a sale of Paladin Labs Inc, its Montreal-based specialty pharmaceutical subsidiary, to Canadian drug maker Knight Therapeutics Inc , people familiar ...

MALVERN, Pa. (AP) -- Endo Health will spend about $1.5 billion to buy the Canadian specialty drug maker Paladin Labs, and both will then be folded into a newly-formed Irish holding company. Endo also ...

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI ® (cenobamate tablets) is now available in Canada. XCOPRI is ...

The product is under investigation for the treatment of Netherton syndrome, a rare disease DUBLIN, July 15, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that its ...

Endo Health Solutions Inc. agreed to buy Canadian specialty-pharmaceutical company Paladin Labs Inc. for about $1.6 billion, allowing Endo to continue its transition into a specialty health-care ...